A groundbreaking discovery led by the University of St Andrews reveals a method to convert household plastic waste into essential components for anti-cancer medications. This innovation focuses on recycling polyethylene terephthalate (PET), commonly found in plastic bottles and textiles, transforming it into a valuable chemical used in pharmaceuticals.
PET waste can be recycled through mechanical or chemical processes. The latter involves breaking down the long polymer chains of PET into smaller units called monomers or other useful chemicals. Researchers published their findings in Angewandte Chemie International Edition, detailing a method using a ruthenium-catalyzed semi-hydrogenation process to depolymerize PET into ethyl-4-hydroxymethyl benzoate (EHMB).
Potential for Medical and Environmental Advancements
EHMB is a critical intermediate in the synthesis of several significant compounds, including the widely-used anti-cancer drug Imatinib, as well as Tranexamic acid, which aids in blood clotting, and the insecticide Fenpyroximate. Traditionally, these medications are produced using fossil-derived feedstocks and hazardous reagents, often generating substantial waste.
The research indicates that this new method of producing EHMB offers considerable environmental advantages compared to existing industrial practices. A comparative hot-spot analysis revealed how this streamlined life cycle assessment can identify which stages of production have the most significant environmental impacts, thus guiding necessary improvements.
In addition, the researchers found that EHMB could be converted into a new, recyclable polyester, further enhancing its value in sustainable practices.
Insights from Research Leaders
Lead author Dr. Amit Kumar, from the School of Chemistry at St Andrews, expressed enthusiasm about the findings. He stated, “We are excited by this discovery, which reimagines PET waste as a promising new feedstock for generating high-value active pharmaceutical ingredients (APIs) and agrochemicals. Although chemical recycling is a key strategy for building a circular economy, many current technologies lack strong economic feasibility.”
He emphasized that transforming plastic waste into high-value products could significantly accelerate the shift towards a circular economy, moving beyond merely reproducing similar classes of plastics.
Professor Evgeny Pidko from TU Delft in the Netherlands, a collaborative partner on the project, highlighted the importance of catalyst efficiency. He noted, “For catalytic upcycling to become practical, the catalyst must operate efficiently at low loadings and maintain activity over long periods.”
He explained that understanding catalyst behavior under reaction conditions is critical for optimizing the system, achieving record turnover numbers of up to 37,000. This insight is vital for enhancing catalyst durability and overall process efficiency.
Dr. Benjamin Kuehne and Dr. Alexander Dauth from the chemical and pharmaceutical company Merck KGaA emphasized the pressing need for sustainable chemical processes. They stated, “Pharmaceutical manufacturing generates substantial amounts of waste per kilogram of product, highlighting the urgent need for innovative sustainable chemical processes and raw materials with reduced environmental footprints.”
The research marks a significant step forward in the quest for sustainable solutions in both medical and environmental sectors, showcasing how recycling efforts can yield valuable results in combating health issues while addressing ecological concerns.
For more information, refer to the article titled “From Plastic Waste to Pharmaceutical Precursors: PET Upcycling through Ruthenium Catalysed Semi-Hydrogenation” in Angewandte Chemie International Edition.
